195 related articles for article (PubMed ID: 12358557)
1. Vaccination against cutaneous leishmaniasis: current status.
Melby PC
Am J Clin Dermatol; 2002; 3(8):557-70. PubMed ID: 12358557
[TBL] [Abstract][Full Text] [Related]
2. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.
Okwor I; Uzonna J
Immunol Res; 2008; 41(2):123-36. PubMed ID: 18389179
[TBL] [Abstract][Full Text] [Related]
3. Vaccines and vaccination strategies against human cutaneous leishmaniasis.
Okwor I; Uzonna J
Hum Vaccin; 2009 May; 5(5):291-301. PubMed ID: 19221514
[TBL] [Abstract][Full Text] [Related]
4. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
5. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
7. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
Seyed N; Peters NC; Rafati S
Front Immunol; 2018; 9():1227. PubMed ID: 29922288
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous leishmaniasis: progress towards a vaccine.
Launois P; Tacchini-Cottier F; Kieny MP
Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
[TBL] [Abstract][Full Text] [Related]
9. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
Okwor I; Kuriakose S; Uzonna J
Vaccine; 2010 Jul; 28(33):5451-7. PubMed ID: 20558242
[TBL] [Abstract][Full Text] [Related]
10.
Lajevardi MS; Gholami E; Taheri T; Sarvnaz H; Habibzadeh S; Seyed N; Mortazavi Y; Rafati S
Front Immunol; 2022; 13():895234. PubMed ID: 35757692
[TBL] [Abstract][Full Text] [Related]
11. Immunity to Lutzomyia whitmani Saliva Protects against Experimental Leishmania braziliensis Infection.
Gomes R; Cavalcanti K; Teixeira C; Carvalho AM; Mattos PS; Cristal JR; Muniz AC; Miranda JC; de Oliveira CI; Barral A
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005078. PubMed ID: 27812113
[TBL] [Abstract][Full Text] [Related]
12. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
13. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
[TBL] [Abstract][Full Text] [Related]
14. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
[TBL] [Abstract][Full Text] [Related]
15. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.
Aebischer T; Wolfram M; Patzer SI; Ilg T; Wiese M; Overath P
Infect Immun; 2000 Mar; 68(3):1328-36. PubMed ID: 10678945
[TBL] [Abstract][Full Text] [Related]
16. Leishmaniasis: recognition and management with a focus on the immunocompromised patient.
Choi CM; Lerner EA
Am J Clin Dermatol; 2002; 3(2):91-105. PubMed ID: 11893221
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.
Kenney RT; Sacks DL; Sypek JP; Vilela L; Gam AA; Evans-Davis K
J Immunol; 1999 Oct; 163(8):4481-8. PubMed ID: 10510390
[TBL] [Abstract][Full Text] [Related]
19. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
20. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
Sharifi I; FeKri AR; Aflatonian MR; Khamesipour A; Nadim A; Mousavi MR; Momeni AZ; Dowlati Y; Godal T; Zicker F; Smith PG; Modabber F
Lancet; 1998 May; 351(9115):1540-3. PubMed ID: 10326536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
